Dr John Bridgeman

Email John

Dr John Bridgeman

2010: Postdoctoral Research Associate, University of Cardiff, T-cell Modulation Group.

2009 – 2010: Postdoctoral Research Associate, Childrens’ Cancer Group, University of Manchester. During my time in the lab of Prof. Vaskar Saha I investigated the functional role of the asparaginyl endopeptidase enzyme legumain. Over-expression of this enzyme has been correlated with poor prognosis in childhood leukaemia. I spent much of the time optimising immnoprecipitation and subcellular fractionation protocols for downstream applications.

2008 – 2009: Postdoctoral Research Associate, Cellular Therapy Group, University of Manchester. The work during this period was a continuation of my PhD studies as detailed below. I spent much of this period investigating the multiple activation mechanisms adopted by CARs to activate gene-modified T-cells.

2004 – 2007: PhD, Cellular Therapy Group, University of Manchester. Under the supervision of Prof. Robert Hawkins and Dr. Dave Gilham my PhD investigated the molecular mechanisms underlying activation of gene-modified T-cells via chimeric antigen receptors (CAR). In particular I spent time investigating aspects of CARs that can be modified to improve function, including mutations that modulate CAR-T-cell receptor interactions, and the addition of costimulatory domains.

2002 – 2003: MSc, Molecular Parasitology and Vector Biology, Universities of Salford, Manchester, & Keele. The main focus of my work for my MSc was investigating the immunobiology of human cestodes.

1999 – 2002: BSc (Hons), Biological Sciences, University of Salford.